Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proglumide with Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT06017323Phase 1Withdrawn
- Sponsor
- Georgetown University
- Start
- Oct 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Proglumide in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Georgetown University. Primary endpoint: Recommended Phase II dose and schedule at 2 years. Planned start Oct 2023; status: withdrawn.
02
Drugs
Proglumide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06017323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06017323.